

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.

FINANCIAL STATEMENTS

YEARS ENDED APRIL 30, 2020 AND 2019

TABLE OF CONTENTS

PAGE NO.

INDEPENDENT AUDITORS' REPORT 3

FINANCIAL STATEMENTS


 Statements of Financial Position 4

 Statements of Activities..... 5

 Statements of Functional Expenses 6

 Statements of Cash Flows 7

 Notes to Financial Statements 8



Adam M. Clearfield, CPA
aclearfield@gcocpafirm.com

Michael J. Ocampo, CPA
mocampo@gcocpafirm.com

Stuart I. Goldman, CPA (Ret.)

CERTIFIED PUBLIC ACCOUNTANTS

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Alzheimer's Fund: Support, Research & Cure, Inc.
Salem, MA

We have audited the accompanying financial statements of Alzheimer's Fund: Support, Research & Cure, Inc. (a non-profit organization), which comprise the statement of financial position as of April 30, 2020 and 2019, and the related statements of activities, functional expenses and cash flows for the years then ended, and related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Alzheimer's Fund: Support, Research & Cure, Inc. as of April 30, 2020 and 2019, and the changes in its net assets and its cash flows for the year then ended, in accordance with accounting principles generally accepted in the United States of America.

Goldman, Clearfield & Ocampo, LLP.

Columbia, MD
September 25, 2020

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
STATEMENTS OF FINANCIAL POSITION
APRIL 30, 2020 AND 2019

	<u>2020</u>	<u>2019</u>
ASSETS		
Cash	\$ 32,930	\$ 5,249
Pledges Receivable	3,127	7,510
Prepaid Expenses	<u>640</u>	<u>682</u>
TOTAL ASSETS	<u>\$ 36,697</u>	<u>\$ 13,441</u>
 LIABILITIES		
Grants Payable	<u>\$ 2,275</u>	<u>\$ 2,208</u>
TOTAL LIABILITIES	<u>2,275</u>	<u>2,208</u>
 NET ASSETS		
Without Donor Restrictions	<u>34,422</u>	<u>11,233</u>
TOTAL LIABILITIES AND NET ASSETS	<u>\$ 36,697</u>	<u>\$ 13,441</u>

The accompanying notes are an integral part of the financial statements.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
STATEMENTS OF ACTIVITIES
YEARS ENDED APRIL 30, 2020 AND 2019

	<u>WITHOUT DONOR RESTRICTIONS</u>	
	<u>2020</u>	<u>2019</u>
REVENUES AND OTHER SUPPORT		
Contributions	\$ 115,545	\$ 20,555
Program Service Fees	<u>5,559</u>	<u>-</u>
TOTAL REVENUES AND OTHER SUPPORT	<u>121,104</u>	<u>20,555</u>
EXPENSES		
Management	10,695	62
Program	<u>87,220</u>	<u>9,260</u>
TOTAL EXPENSES	<u>97,915</u>	<u>9,322</u>
INCREASE IN NET ASSETS	23,189	11,233
NET ASSETS - BEGINNING	<u>11,233</u>	<u>-</u>
NET ASSETS - ENDING	<u>\$ 34,422</u>	<u>\$ 11,233</u>

The accompanying notes are an integral part of the financial statements.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
STATEMENTS OF FUNCTIONAL EXPENSES
YEARS ENDED APRIL 30, 2020 AND 2019

	2020		
	MANAGEMENT	PROGRAM	TOTAL
Filing Fees	\$ -	\$ 6,252	\$ 6,252
Grants	-	26,968	26,968
Insurance	740	-	740
Office Expense	130	-	130
Professional Fees	3,825	-	3,825
Support Services	6,000	54,000	60,000
	\$ 10,695	\$ 87,220	\$ 97,915

	2019		
	MANAGEMENT	PROGRAM	TOTAL
Filing Fees	\$ -	\$ 7,052	\$ 7,052
Grants	-	2,208	2,208
Insurance	62	-	62
	\$ 62	\$ 9,260	\$ 9,322

The accompanying notes are an integral part of the financial statements.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
STATEMENTS OF CASH FLOWS
YEARS ENDED APRIL 30, 2020 AND 2019

	<u>2020</u>	<u>2019</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Increase in Net Assets	\$ 23,189	\$ 11,233
Adjustments to Reconcile Changes in Net Assets to Net Cash Provided by Operating Activities:		
(Increase) Decrease in:		
Pledges Receivable	4,383	(7,510)
Prepaid Expenses	42	(682)
Increase (Decrease) in:		
Grants Payable	<u>67</u>	<u>2,208</u>
NET CASH PROVIDED BY OPERATING ACTIVITIES	<u>27,681</u>	<u>5,249</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	27,681	5,249
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	<u>5,249</u>	<u>-</u>
CASH AND CASH EQUIVALENTS - END OF YEAR	<u>\$ 32,930</u>	<u>\$ 5,249</u>

The accompanying notes are an integral part of the financial statements.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2020 AND 2019

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization:

Alzheimer's Fund: Support, Research & Cure, Inc. was incorporated under the laws of Massachusetts as a non-profit organization and is exempt from income taxes on its exempt activities under Section 501(c)(3) of the Internal Revenue Code.

The Organization's primary purpose is to assist other tax-exempt organizations in participating in workplace fundraising drives such as the U.S. Government's Combined Federal Campaign. The Organization screens applications for such drives, assists with the transfer of funds from donors to the benefiting groups, educates the staff and volunteers of these groups so that they better understand workplace giving programs, and assists in the marketing of such groups to potential donors.

Income Taxes:

The Organization's Return of Organization Exempt from Income Tax (Form 990) for the years ended April 30, 2020 and 2019 is subject to examination, generally, for three years after it was filed. The Organization filed a 990-N for the year ended April 30, 2018.

The Organization is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code, except on net income derived from unrelated business activities. The Organization does not have any income from unrelated business activities. The Organization believes that it has appropriate support for any tax positions taken, and as such, does not have any uncertain tax positions that are material to the financial statements.

Subsequent Events:

In the normal course of preparing the Organization's financial statements, management reviews events that occur after the statement of financial position dated April 30, 2020 for potential recognition or disclosure in the financial statements. Management has evaluated subsequent events through September 25, 2020, which is the date the financial statements were available to be issued.

Method of Accounting:

The Organization's financial statements have been prepared on the accrual basis of accounting. Consequently, revenue is recognized when earned and expenses when incurred.

Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2020 AND 2019
(CONTINUED)

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Cash and Cash Equivalents:

For the purposes of the statement of cash flows, the Organization considers all highly liquid investments available for current use with an initial maturity of three months or less to be cash equivalents.

Pledges Receivable:

Pledges Receivable have been reviewed by management and considered fully collectible.

Financial Statement Presentation:

The net assets of the Organization and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the organization. These net assets may be used at the discretion of Alzheimer's Fund: Support, Research & Cure, Inc.'s management and board of directors.

Net Assets With Donor Restrictions – Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of Alzheimer's Fund: Support, Research & Cure, Inc. or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statements of activities.

New Accounting Pronouncements:

On August 18, 2016, FASB issued ASU 2016-14, Not-for-Profit Entities (Topic 958) – *Presentation of Financial Statements of Not-for-Profit Entities*. The update addresses the complexity and understandability of net asset classification, deficiencies in information about liquidity and availability of resources, and the lack of consistency in the type of information provided about expenses and investment return. Alzheimer's Fund: Support, Research & Cure, Inc. adopted the ASU the prior fiscal year.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2020 AND 2019
(CONTINUED)

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

New Accounting Pronouncements (Continued):

In June 2018, the FASB issued ASU 2018-08, *Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*. ASU 2018-08 was issued to clarify and improve the guidance in GAAP for distinguishing transactions that are contributions from those that are exchange transactions. The ASU also provides guidance for determining if a contribution is conditional. The amendments in ASU 2018-08 address these matters for both contributions received (income or revenue) and contributions made (expense). The Organization has determined there is no impact in the presentation of these statements when applying ASU 2018-08.

NOTE B – AVAILABILITY AND LIQUIDITY

As of April 30, 2020, Alzheimer's Fund: Support, Research & Cure, Inc. has \$36,057 of financial assets available within one year of the balance sheet date to meet cash needs for general expenditure, consisting of cash of \$32,930 and pledges receivable of \$3,127. As of April 30, 2019, Alzheimer's Fund: Support, Research & Cure, Inc. has \$12,759 of financial assets available within one year of the balance sheet date to meet cash needs for general expenditure, consisting of cash of \$5,249 and pledges receivable of \$7,510. None of the financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date. The receivables are subject to implied time restrictions but are expected to be collected within one year. Alzheimer's Fund: Support, Research & Cure, Inc.'s goal is generally to maintain financial assets to meet 30 days' worth of operating expenses.

NOTE C – FUNCTIONAL EXPENSES

The cost of providing program and other activities have been summarized on a functional basis in the statement of activities. Certain costs have been allocated among management and program services benefited. Such allocations are determined by management on an equitable basis.

NOTE D – DISTRIBUTIONS TO MEMBER CHARITIES

The Organization distributes a proportionate share of receipts based on the results of each individual campaign. The proportionate share of receipts is determined by donor designations to the individual member organization, as reported by campaign administrators.

ALZHEIMER'S FUND: SUPPORT, RESEARCH & CURE, INC.
NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2020 AND 2019
(CONTINUED)

NOTE E – CONTINGENCIES

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) as a pandemic, which continues to spread throughout the United States. The Organization could be materially and adversely affected by the risks, or the public perception of the risks, related to an epidemic, pandemic, outbreak, or other public health crisis, such as the recent outbreak of COVID-19. The ultimate extent of the impact of any epidemic, pandemic or other health crisis on the business, financial condition, and results of operations will depend on future developments, which are uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic or other health crisis and actions taken to contain or prevent their further spread, among others. Accordingly, the Organization cannot predict the extent to which the financial condition and results of operations will be affected.